Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2026)

Foghorn Therapeutics' FCF Margin history runs 7 years deep, the most recent figure standing at 773.37% for Q1 2026.

• In Q1 2026, FCF Margin fell 37021.0% year-over-year to 773.37%; the TTM figure through Mar 2026 stood at 309.56% (up 9830.0% YoY), while the FY2025 annual figure was 278.56%, up 16969.0% from the prior year.
• FCF Margin for Q1 2026 stood at 773.37%, down from 240.85% in the prior quarter.
• The five-year high for FCF Margin was 6920.59% in Q1 2022, with the low at 875.28% in Q4 2024.
• The 5-year median for FCF Margin is 403.16% (2025), against an average of 33.21%.
• The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 5027072 bps in 2022, then plunged 751350 bps in 2023.
• Foghorn Therapeutics' FCF Margin stood at 690.25% in 2022, then climbed by 28 bps to 497.61% in 2023, then tumbled by 76 bps to 875.28% in 2024, then surged by 72 bps to 240.85% in 2025, then tumbled by 221 bps to 773.37% in 2026.
• Business Quant data shows FHTX's FCF Margin at 773.37% in Q1 2026, 240.85% in Q4 2025, and 231.33% in Q3 2025.